Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04691502 plus letrozole versus letrozole alone in ER-positive, HER2-negative breast cancer
2011-003044-53Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PF-04691502 and letrozole in breast cancer (3 arms), sponsored by Pfizer. Primary endpoint: Adverse events. Started Oct 2011; status: terminated.
02
Drugs
PF-04691502letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-003044-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003044-53.